Celularity, Inc.
https://www.celularity.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celularity, Inc.
Deal Watch: Sanofi Teams Up With Biond On Novel Checkpoint Inhibitor
Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.
Mesoblast, Athersys Take Lead In Race To Develop Stem Cell Therapies For COVID-19
Phase II/III studies are underway for Mesoblast’s remestemcel-L and Athersys’ Multistem, followed by a pack of earlier-stage stem cell candidates from Pluristem, Hope Bioscience and Celltex – with an interactive chart of the COVID-19 cell therapy pipeline.
ASH First Look: CAR-T Therapies Against BCMA, CD19 And More
CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates with novel constructs and targets.
Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution
Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions...
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- CariCord
- GX Acquisition Corp.